Evofosfamide (TH-302)是一种缺氧激活前药,其细胞毒性在缺氧与常氧条件下差异显著。
|
英文别名 (English Synonym) |
TH-302 |
|
中文名称 (Chinese Name) |
艾伏磷酰胺 |
|
靶点 (Target) |
Topoisomerase |
|
通路 (Pathway) |
Cell Cycle/DNA Damage |
|
CAS号 (CAS NO.) |
918633-87-1 |
|
分子式 (Formula) |
C9H16Br2N5O4P |
|
分子量 (Molecular Weight) |
449.04 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Meng F, Bhupathi D, Sun JD, Liu Q, Ahluwalia D, Wang Y, Matteucci MD, Hart CP. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition. BMC Cancer. 2015 May 21,15:422. doi: 10.1186/s12885-015-1387-6. PMID: 25994202, PMCID: PMC4453293.[2]Zhang X, Wojtkowiak JW, Martinez GV, Cornnell HH, Hart CP, Baker AF, Gillies R. MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts. PLoS One. 2016 May 26,11(5):e0155289. doi: 10.1371/journal.pone.0155289. PMID: 27227903, PMCID: PMC4882075.
